Enveric Bolsters Neuroplastogen Patent Portfolio with New U.S. Issuance
Event summary
- Enveric Biosciences received U.S. Patent No. 12,577,232 on March 17, 2026, covering its EVM301 series of molecules.
- The patent claims chemical compounds, formulations, and treatment methods for neurological disorders, building on existing patent No. 12,338,231.
- EVM301 series includes EB-003, a lead candidate for mental health disorders, designed as a 5-HT2A / 5-HT1B dual-acting compound.
- Enveric holds 27 issued U.S. patents and approximately 60 pending international applications related to its neuroplastogenic compounds.
The big picture
The patent strengthens Enveric’s position in a crowded neurotherapeutic market, where novel approaches to treating psychiatric disorders are increasingly sought after. Neuroplastogenic therapies represent a potential paradigm shift from traditional antidepressants, but face significant clinical and regulatory hurdles. This patent provides a degree of exclusivity, but the ultimate value will depend on clinical trial outcomes and market adoption.
What we're watching
- Clinical Progress
- The success of Enveric's planned IND application submission to the FDA and subsequent Phase 1 trial will be critical to validating the EVM301 series' potential and justifying the patent estate's value.
- Competitive Landscape
- How Enveric differentiates its neuroplastogenic approach from emerging competitors in the psychiatric and neurological disorder space will determine its long-term market position.
- Patent Defense
- The strength and defensibility of Enveric's patent portfolio, particularly given the complexity of tryptamine derivatives, will influence its ability to protect its intellectual property and maintain a competitive advantage.
Related topics